Rankings
▼
Calendar
▼
CRNX Q2 2017 Earnings Report — Crinetics Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
Crinetics Pharmaceuticals, Inc.
CRNX
Q2 2017 Earnings
Reported June 29, 2017
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q2 2017
Q1 2017
Q2 2016
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$2M
-$3M
—
37.0%
—
EPS (Diluted)
$-0.12
$-0.19
—
36.8%
—
Free Cash Flow
-$2M
-$2M
—
4.8%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$2M
Selling & Marketing
$0
General & Administrative
$392.0K
SG&A Expenses
$392.0K
Other Expenses
-$832.0K
Operating Expenses
$2M
Cost & Expenses
$2M
OPERATING INCOME
-$2M
Interest Income
$7.0K
Interest Expense
$3.0K
Other Income/Expenses
-$5.0K
INCOME BEFORE TAX
-$2M
Income Tax Expense
$0
Net Income from Continuing Ops
-$2M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$2M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$2M
D&A
$25.0K
EBIT
-$2M
EBITDA
-$2M
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$2M
Depreciation & Amortization
$25.0K
Stock-Based Compensation
$72.0K
Deferred Income Tax
$0
Other Non-Cash Items
-$150.0K
Change in Working Capital
-$648.0K
OPERATING CASH FLOW
-$2M
Capital Expenditure
-$35.0K
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
$0
NET CASH FROM INVESTING
-$35.0K
Net Debt Issuance
-$11.0K
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$0
NET CASH FROM FINANCING
$5M
FREE CASH FLOW
-$2M
Net Change in Cash
$2M
marketcaparena.com
← FY 2017
CRNX Overview
Q3 2017 →